Brief: Interim Findings From Mirage Phase III Randomized Trial Signal Superiority Of Mridian Mri-Guidance In Stereotactic Body Radiotherapy
15/02/2022 13:15
Feb 15 (Reuters) - ViewRay Inc VRAY.O :
* INTERIM FINDINGS FROM MIRAGE PHASE III RANDOMIZED TRIAL
SIGNAL
SUPERIORITY OF MRIDIAN® MRI-GUIDANCE IN STEREOTACTIC BODY
RADIOTHERAPY (SBRT) FOR LOCALIZED PROSTATE CANCER
Source text for Eikon: ID:nPn43s1dGa
Further company coverage: VRAY.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Viewray
See all newsBrief: ViewRay Announces Commencement Of Nasdaq Delisting Proceedings Common Stock Expected To Begin Trading On The OTC Markets
Press Digest: Wall Street Journal - July 18
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
ViewRay hits record low on filing for voluntary Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global